IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IRulya Therapeutics (Nasdaq: IRLA) granted restricted stock units representing 83,513 common shares as employment inducements for new employees.
The awards went to three new employees under the 2026 Inducement Plan. Vesting requires continued employment or service through each applicable vesting date. The first 25% vests on the last day of the calendar quarter containing the first anniversary of the Vesting Commencement Date; 6.25% vests at each quarter-end thereafter. The board approved the grants under Nasdaq Listing Rule 5635(c)(4), and the awards remain subject to the plan and applicable restricted stock unit agreements.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.83,513 common shares underlying employee restricted stock units create potential dilution as the awards vest.
Details
News Market Reaction – IRLA
On Nov 10, the first trading day after this news, IRLA closed 14.34% above the previous close. Argus tracked a peak move of +8.4% during that session. Our momentum scanner recorded 11 alerts for this stock that day. That session’s volume was 1.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 10 session.
Key Figures
- Restricted stock units granted
- 83,513 shares
- Inducement grants to new employees
- Recipients
- 3 employees
- New employees receiving inducement grants
- Initial vesting
- 25%
- On the last day of the calendar quarter in which the first anniversary of the Vesting Commencement Date occurs
- Subsequent vesting
- 6.25%
- At the end of each calendar quarter thereafter
Key Terms
restricted stock units financial
vesting commencement date financial
nasdaq rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that on November 9, 2026, IRulya granted restricted stock units representing a total of 83,513 shares of common stock to three (3) new employees.
These inducement grants were granted pursuant to the IRulya Therapeutics Inc. 2026 Inducement Plan, subject to recipient’s continued employment or service through each applicable vesting date. Twenty-five percent (
The inducement grants were approved by IRulya’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About IRulya Therapeutics Inc.
IRulya Therapeutics Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH). A Phase 2a clinical study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b clinical study in PH-ILD is ongoing, and a Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Contact
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do IRulya Therapeutics' employee inducement grants vest?
The first 25% vests on the last day of the calendar quarter containing the first anniversary of the Vesting Commencement Date, followed by 6.25% at each calendar quarter-end thereafter. Recipients must remain employed or in service through each applicable vesting date.